Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Primary objectives
1. To determine whether induction of apoptosis or inhibition of angiogenesis are involved
in the antitumor activity of (Gleevec, Formerly STI-571) in patients with
gastrointestinal stromal tumors (GIST) as assessed by Positron Emission Tomography (PET)
scanning.
2. To determine whether dynamic computed tomography (CT), PET scan, molecular and
histopathologic responses in GIST tumors from patients treated with Gleevec predict
Disease-Free Survival (DFS) time.
Secondary objectives
1. To determine the disease free survival of patients with resectable or partially
resectable gastrointestinal stromal tumors treated with Gleevec preoperatively and
continued for 2 years after resection of disease.
2. To assess the safety and tolerability of Gleevec given to patients with GI stromal
tumors 3, 5, or 7 days preoperatively and continued postoperatively.